Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY
Anthem Biosciences Ltd · Press Release · 03 Nov 2026, 11:37 pm
Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY Anthem Biosciences reported a 7.9% YoY increase in Q2FY27 consolidated revenue from operations to ₹5,940 Mn (up 42.0% QoQ), led by CRDMO revenue of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins reaching 50.6%, while PAT rose 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1 FY27, revenue stood at ₹10,123 Mn, EBITDA at ₹5,059 Mn (46.2% margin), and PAT at ₹3,314 Mn. As of 30th Sep'26, the company held a net cash position of ₹15,380 Mn.
Original exchange filing (PDF)
More announcements from Anthem Biosciences Ltd
- Transcript of Q2 & H1 FY27 Earnings Conference Call · 06 Nov 2026
- Audio recording of Earnings Call for the quarter ended September 30, 2026. · 05 Nov 2026
- Intimation of Schedule of Analyst Meet/Institutional Meet · 05 Nov 2026
- Investors presentation for the financial results for the quarter and half year ended September 30, 2026. · 03 Nov 2026
- Submission of the outcome of the Board Meeting held on November 03, 2026, for approval of the Unaudited Financial results for the quarter and half year ended September 30, 2026. · 03 Nov 2026
- Submission of outcome of the Board Meeting approving the Unaudited Financial results for the quarter and half year ended September 30, 2026, on November 03, 2026 · 03 Nov 2026
- Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026. · 03 Nov 2026
- Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 04 Nov 2026
